Evidence map›Paper›PMID 40806072›Full record

Observational studyNutrients2025

Relationship Between Body Composition and Biomarkers in Adult Females with Breast Cancer: 1-Year Follow-Up Prospective Study.

Angélica Larrad-Sáinz, María Gemma Hernández Núñez, Ana Barabash Bustelo, Inés Gil Prados, Johanna Valerio, José Luis Espadas Gil, María Eugenia Olivares Crespo, María Herrera de la Muela, Blanca Bernaldo Madrid, Irene Serrano García and 5 more

Abstract readObservational Study
In one paragraph

Observational study in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Angélica Larrad-SáinzEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0001-7331-7672
María Gemma Hernández NúñezEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Ana Barabash BusteloEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Inés Gil PradosObstetrics and Gynecology Breast Cancer Unit, Women Health Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.ORCID 0000-0002-8192-2140
Johanna ValerioEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0003-4562-5381
José Luis Espadas GilEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
María Eugenia Olivares CrespoPsichooncology, Breast Cancer Unit, Women Health Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.
María Herrera de la MuelaObstetrics and Gynecology Breast Cancer Unit, Women Health Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.ORCID 0000-0003-3440-9413
Blanca Bernaldo MadridEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0009-0007-8027-7614
Irene Serrano GarcíaUnidad de Apoyo a la Investigación, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0001-7184-5447
Ignacio Cristóbal GarcíaObstetrics and Gynecology Breast Cancer Unit, Women Health Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.ORCID 0000-0002-2793-6592
Miguel Ángel Rubio-HerreraEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0002-0495-6240
Alfonso Luis Calle-PascualEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0002-3628-9323
Juana María Brenes SánchezObstetrics and Gynecology Breast Cancer Unit, Women Health Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.ORCID 0000-0002-7698-9893
Pilar Matía-MartínEndocrinology and Nutrition Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0001-9844-3755

Funding

European Union-NextGenerationEU, through the Instituto de Salud Carlos III AC21_2/00036Fundación de Investigación en Nutrición y Metabolismo (FINUMET) 2025Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid (SENDIMAD) 2020Sociedad Española de Endocrinología y Nutrición 2020
6 · The paper itself

Abstract

BACKGROUND/

objectivesAfter diagnosis, it is common for women with breast cancer to gain weight, which is associated with worse clinical outcomes. However, traditional measures such as body weight, BMI, and waist circumference do not detect key changes in body composition, such as fat redistribution or muscle loss. The objective of this exploratory study was to assess the evolution of body composition and muscle strength after one year of treatment, and their relationship with metabolic biomarkers.

methodsProspective observational study in newly diagnosed breast cancer patients. Body composition was assessed using bioelectrical impedance analysis (BIA) and ultrasound (US); muscle strength was measured by handgrip dynamometry. Biomarkers analyzed included glucose, insulin, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), glycosylated hemoglobin (HbA1c), total cholesterol (and its fractions), triglycerides, C-reactive protein (CRP), 6-interleukin (IL-6), vitamin D, myostatin, and fibroblast growth factor 21 (FGF-21).

resultsSixty-one women (mean age 58 years) were included. After one year, fat mass and related parameters significantly increased, while skeletal muscle mass and muscle strength decreased. Sarcopenic obesity prevalence rose from 1.16% to 4.9%. No significant changes were found in biomarkers, but positive correlations were observed between fat parameters and insulin, HOMA-IR, and triglycerides, and negative correlations with HDL-cholesterol.

conclusionsBIA and US can detect unfavorable changes in body composition that are not reflected in conventional measurements. At one year post-diagnosis, women showed increased fat accumulation, muscle loss, and reduced strength, even without significant metabolic biomarker changes. Further research is warranted to elucidate the long-term clinical implications of these findings and the external validity in larger cohorts.

Indexed as

Body CompositionBreast NeoplasmsAdultAgedBiomarkersBody Mass IndexElectric ImpedanceFemaleFollow-Up StudiesHand StrengthHumansInsulinInsulin ResistanceMiddle AgedMuscle, SkeletalMuscle StrengthBiomarkersInsulinbioimpedancebody compositionbreast cancersarcopenic obesityultrasonography

Identifiers

PMID40806072
PMCPMC12348593

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.